adenovir
ad
vector
use
varieti
vaccin
applic
includ
cancer
infecti
diseas
ad
vector
util
vaccin
vector
sever
attribut
broad
util
profil
deriv
sever
key
attribut
viral
genom
readili
manipul
allow
deriv
recombin
virus
b
replicationdefect
ad
deriv
propag
easili
complement
cell
line
make
product
larg
scale
vaccin
feasibl
c
ad
infect
broad
rang
target
cell
possess
larg
gene
deliveri
payload
e
vector
achiev
unparallel
level
vivo
gene
transfer
high
level
induc
transgen
express
tradit
adbas
vaccin
design
express
antigen
transgen
express
given
antigen
howev
case
convent
adbas
vaccin
suboptim
clinic
result
suboptim
result
attribut
part
preexist
ad
serotyp
immun
adult
popul
preexist
immun
pei
therefor
individu
vaccin
ad
vector
therapeut
purpos
mayb
limit
transgeneantigen
express
individu
regard
antigen
capsidincorpor
strategi
develop
circumv
drawback
associ
convent
transgen
express
antigen
within
ad
strategi
embodi
incorpor
antigen
peptid
within
capsid
structur
viral
vector
antigen
capsidincorpor
strategi
use
adbas
vaccin
context
mani
diseas
one
first
instanc
wherebi
antigen
capsidincorpor
strategi
use
research
perform
crompton
crompton
colleagu
insert
eight
amino
acid
sequenc
capsid
protein
polioviru
type
two
region
adenoviru
serotyp
hexon
one
chimer
vector
produc
methodolog
grew
well
tissu
cultur
antiserum
rais
ad
polio
insert
specif
recogn
capsid
polio
type
use
antigen
capsidincorpor
strategi
develop
mean
incorpor
heterolog
peptid
epitop
specif
within
major
surfaceexpos
domain
ad
capsid
protein
hexon
major
capsid
protein
hexon
util
antigen
capsid
incorpor
strategi
due
hexon
natur
role
gener
antiad
immun
respons
numer
represent
within
ad
virion
note
previou
work
shown
incorpor
small
heterolog
peptid
ad
hexon
hypervari
region
hvr
without
perturb
viral
viabil
biolog
characterist
publish
studi
focus
antigen
andor
epitop
incorpor
singl
site
antigenepitop
incorpor
fiber
protein
ix
pix
regard
antigen
epitop
includ
linker
sequenc
rang
size
nine
fortyf
amino
acid
incorpor
within
hexon
region
hexon
region
epitop
incorpor
includ
epitop
deriv
polio
pseudomona
aeruginosa
b
anthraci
hiv
well
model
epitop
base
abil
manipul
site
recent
sought
explor
rel
merit
antigen
incorpor
within
two
hexon
local
order
accomplish
compar
flexibl
capac
respect
genet
incorpor
ident
model
epitop
increas
size
within
hexon
previou
studi
demonstr
hexonincorpor
model
antigen
elicit
rang
immun
respons
depend
antigen
placement
antigen
size
either
local
studi
confirm
could
potenti
incorpor
site
antigen
consider
size
vaccin
vector
display
incorpor
feasibl
vaccin
develop
studi
herein
focus
creation
multival
vaccin
vector
present
hiv
antigen
context
ad
capsid
protein
hexon
well
express
hiv
antigen
transgen
specif
novel
vector
util
hexon
incorpor
site
twentyfour
amino
acid
region
eknekelleldkwaslwnwfditn
hiv
membran
proxim
ectodomain
region
mper
deriv
hiv
glycoprotein
addit
present
mper
within
vector
express
hivspecif
protein
gag
region
studi
herein
illustr
multival
antihiv
vector
elicit
humor
cellular
antihiv
respons
furthermor
vaccin
vector
present
model
antigen
elicit
hiv
epitopespecif
humor
immun
respons
studi
monoclon
antibodi
cat
use
follow
reagent
obtain
nih
aid
research
refer
reagent
program
divis
aid
niaid
nih
monoclon
antibodi
gener
dr
hermann
kating
human
monoclon
antibodi
specif
eldkwa
epitop
goat
antihuman
hors
radish
peroxidas
hrp
antibodi
purchas
southern
biotech
birmingham
al
human
embryon
kidney
cell
obtain
cultur
medium
recommend
american
type
cultur
collect
manassa
va
cell
line
incub
humidifi
condit
order
gener
recombin
adenovirus
mper
insert
within
hexon
region
fragment
dna
correspond
mper
gener
pcr
templat
provid
integr
dna
technolog
manuscript
mper
sequenc
correspond
eknekelleldkwaslwnwfditn
hiv
fragment
subclon
bamhi
site
previous
describ
plasmid
creat
vector
contain
hiv
epitop
hvr
hexon
result
plasmid
digest
ecori
pmei
result
fragment
contain
homolog
recombin
region
hexon
gene
purifi
recombin
swaidigest
backbon
vector
lack
hexon
gene
recombin
reaction
perform
escherichia
coli
stratagen
la
jolla
ca
result
clone
design
addit
anoth
viru
construct
hexon
modif
contain
hiv
gag
gene
region
gag
creat
vector
contain
hiv
gag
cytomegaloviru
cmv
gag
construct
subclon
ad
shuttl
plasmid
result
plasmid
digest
pmei
restrict
enzym
result
fragment
contain
homolog
recombin
region
region
recombin
delet
backbon
adcmvenv
made
previous
describ
vector
express
hiv
envelop
env
gene
control
cmv
promot
rescu
virus
construct
plasmid
digest
paci
two
dna
transfect
lipofectamin
reagent
invitrogen
carlsbad
ca
cell
follow
plaqu
format
process
largescal
propag
cell
virus
purifi
doubl
cesium
chlorid
ultracentrifug
dialyz
phosphatebuff
salin
contain
glycerol
virus
store
use
final
aliquot
viru
analyz
physic
titer
use
absorb
nm
infecti
viral
titer
ifu
per
ml
determin
tissu
cultur
infecti
dose
assay
titer
calcul
use
karber
statist
method
titer
ml
log
dilut
sum
ratio
first
dilut
modif
hexon
gene
confirm
pcr
analysi
primer
sens
ctcacgtatttgggcaggcgcc
antisens
ggcatgtaagaaatatg
agtgtctggg
anneal
downstream
site
insert
within
hexon
open
read
frame
analyz
gag
express
brief
cell
infect
variou
vector
ifu
per
cell
cell
lysat
collect
hour
subject
four
freezethaw
cycl
obtain
crude
cell
lysat
protein
boil
laemmli
sampl
buffer
minut
resolv
sodium
dodecyl
sulfatepolyacrylamid
gel
protein
transfer
polyvinyliden
fluorid
membran
stain
perform
gag
antibodi
affiantihiv
matrix
igi
genway
biotech
inc
follow
secondari
stain
hrplink
goatchicken
igi
ave
lab
inc
protein
detect
polyvinyliden
fluorid
membran
stain
tablet
sigmaaldrich
st
loui
mo
brief
analyz
mper
present
select
vector
viral
particl
vp
boil
laemmli
sampl
buffer
minut
resolv
sodium
dodecyl
sulfatepolyacrylamid
gel
protein
transfer
polyvinyliden
fluorid
membran
stain
perform
monoclon
antibodi
follow
secondari
stain
hrpconjug
goat
antihuman
antibodi
protein
detect
polyvinyliden
fluorid
membran
stain
tablet
sigmaaldrich
st
loui
mo
enzymelink
immunosorb
assay
elisa
perform
essenti
describ
previous
order
determin
mper
peptid
surfac
expos
ad
virion
whole
viru
elisa
perform
briefli
differ
amount
virus
rang
vp
immobil
plate
nunc
maxisorp
rochest
ny
overnight
incub
mm
carbon
buffer
ph
per
well
wash
tween
phosphatebuff
salin
pb
block
block
solut
bovin
serum
albumin
tween
pb
immobil
virus
incub
antihiv
monoclon
antibodi
cat
hr
room
temperatur
rt
follow
incub
apconjug
goat
antihuman
antibodi
colormetr
reaction
perform
pnitrophenyl
phosphat
sigmaaldrich
st
loui
mo
recommend
manufactur
optic
densiti
nm
determin
micropl
reader
molecular
devic
antimp
respons
elisa
plate
nunc
maxisorp
rochest
ny
coat
mper
peptid
genscript
co
piscataway
nj
mm
carbon
ph
per
well
accord
method
describ
previous
plate
wash
block
bsapb
wash
dilut
sera
ad
incub
least
hr
rt
plate
extens
wash
block
bsapb
plate
wash
hrpconjug
goat
antihuman
antibodi
southern
biotech
birmingham
al
elisa
develop
tmb
substrat
order
determin
mper
isotypespecif
reactiv
elisa
plate
coat
mper
peptid
mm
carbon
ph
per
well
accord
method
describ
previous
plate
wash
block
bsapb
wash
dilut
sera
ad
incub
least
hr
rt
plate
extens
wash
block
bsapb
isotypespecif
mous
antibodi
sigmaaldrich
st
loui
mo
bound
elisa
plate
plate
wash
hrpconjug
antimous
antibodi
dako
denmak
denmark
elisa
develop
tmb
substrat
sigmaaldrich
st
loui
mo
measur
emax
micropl
reader
growth
kinet
ad
vector
obtain
essenti
describ
previous
cell
plate
plate
densiti
cell
per
well
h
infect
cell
infect
ad
vpscell
growth
medium
contain
fb
ml
growth
medium
contain
fb
ad
well
h
incub
humidifi
incub
infect
cell
monitor
harvest
medium
variou
time
point
postinfect
complet
cpe
form
collect
cell
togeth
medium
lyse
four
cycl
subject
centrifug
min
cell
debri
remov
total
virus
well
determin
multipli
titer
total
volum
supernat
plot
growth
curv
heat
inactiv
assay
perform
essenti
describ
previous
briefli
virus
incub
min
either
pb
without
growth
medium
contain
fb
infecti
titer
redetermin
standard
method
adeasi
vector
system
qbiogen
inc
carlsbad
ca
one
day
analysi
cell
plu
growth
medium
fetal
bovin
serum
fb
ad
flat
bottom
plate
eight
serial
dilut
viru
rang
made
medium
contain
fb
depend
viru
dilut
ad
plate
one
row
dilut
incub
day
humidifi
incub
plate
examin
cytopath
effect
cpe
microscop
observ
cpe
contain
well
count
row
order
determin
ratio
posit
well
per
row
plate
titer
calcul
use
follow
experi
perform
determin
antibodi
respons
immun
ad
vector
femal
balbc
mice
week
age
obtain
jackson
laboratori
bar
harbor
group
least
eight
mice
analyz
experi
time
point
ad
inject
group
mice
gag
adcmvgag
adcmvenv
vp
per
mous
use
intramuscular
im
inject
mice
boost
day
prime
vp
vector
cell
respons
analysi
blood
collect
mice
vaccin
gag
adcmvgag
anim
protocol
approv
institut
anim
care
use
committe
univers
alabama
birmingham
antigen
epitop
hiv
mper
deriv
gener
express
plasmid
genscript
co
piscataway
nj
peptid
use
posit
control
elisa
assay
peptid
pure
indic
analyt
highperform
liquid
chromatographi
peptid
dissolv
dmso
concentr
mm
store
use
flow
cytometr
analysi
gag
gene
express
cell
qbiogen
inc
infect
vpcell
either
adcmvgag
gag
ad
vector
hour
presenc
differ
amount
human
ascit
cell
permeabil
cytofixcytoperm
bd
bioscienc
min
wash
three
time
perm
wash
buffer
bd
bioscienc
cell
incub
dilut
monoclon
antibodi
min
cell
wash
incub
dilut
peconjug
antimous
igg
bd
farmingen
min
cell
wash
analyz
facscalibur
flow
cytomet
bd
bioscienc
data
acquir
cellquest
softwar
analyz
flowjo
version
softwar
mice
vaccin
boost
describ
peripher
blood
gagspecif
cell
enumer
flow
cytometr
analys
whole
blood
collect
heparin
pb
day
follow
initi
vaccin
leukocyt
collect
use
lymphocyt
separ
medium
mediatech
inc
manassa
va
cell
collect
wash
twice
bsa
edta
pb
count
one
two
million
lymphocyt
stain
without
gag
tetram
apc
creat
emori
univers
cocktail
antibodi
bd
pharmingen
san
jose
california
cell
wash
bsa
edta
pb
cell
fix
paraformaldehyd
subsequ
analyz
flow
cytometri
lsr
ii
cytomet
analysi
cell
collect
per
sampl
data
present
mean
standard
error
statist
analys
perform
nonpair
twotail
student
test
assum
equal
varianc
statist
signific
defin
p
establish
technic
feasibl
allow
us
place
epitop
sought
explor
whether
could
present
hiv
antigen
within
ad
protein
hexon
well
express
hiv
antigen
transgen
within
rational
choos
portion
mper
eknekelleldkwaslwnwfditn
deriv
incorpor
ad
capsid
base
fact
envelop
protein
ectodomain
target
three
broadli
neutral
antibodi
antigen
function
conform
depend
therefor
plan
insert
linker
sequenc
onto
mper
core
region
order
mper
epitop
present
ad
capsid
close
natur
conform
possibl
vaccin
vector
design
also
embodi
incorpor
hiv
gag
gene
within
ad
region
hiv
gag
gene
major
structur
protein
hiv
viru
gag
protein
frequent
use
hiv
vaccin
scheme
dna
sequenc
correspond
amino
acid
region
mper
plu
amino
acid
linker
amplifi
pcr
clone
hexon
shuttl
vector
previous
describ
addit
hiv
gag
gene
subclon
shuttl
vector
control
cmv
promot
transfer
genom
gag
homolog
recombin
addit
control
vector
gener
contain
genom
combin
mper
within
hexon
region
control
ad
genom
express
gag
gene
cmv
promot
hexon
modif
adcmvgag
gener
studi
well
result
ad
genom
partial
sequenc
confirm
correct
gene
incorpor
subsequ
transfect
cell
result
recombin
genom
result
rescu
follow
vector
adcmvgag
gag
order
confirm
vector
ident
hexon
gagspecif
pcr
analys
perform
use
genom
dna
purifi
virion
figur
regard
hexonspecif
pcr
adcmvgag
found
wild
type
hexon
pcr
profil
produc
base
pair
bp
pcr
fragment
use
hexonspecif
primer
design
amplifi
region
figur
lane
hexon
specif
pcr
gag
construct
reveal
bp
fragment
suggest
expect
insert
figur
lane
addit
bp
figur
lane
indic
incorpor
dna
within
hexon
region
adcmvgag
gag
found
posit
gagspecif
pcr
assay
produc
bp
product
gagspecif
pcr
primer
figur
lane
respect
diagram
depict
vector
construct
vector
use
studi
illustr
figur
success
incorpor
hiv
gene
next
sought
verifi
express
transgen
capsid
incorpor
protein
level
western
blot
analysi
cell
infect
unmodifi
neg
control
one
hivgag
contain
virus
gag
adcmvgag
respect
cell
lysat
prepar
hour
postinfect
subject
western
blot
analysi
antigagspecif
antibodi
gag
protein
express
evidenc
presenc
kda
molecular
weight
protein
band
lysat
cell
infect
either
hexonmodifi
gag
express
vector
gag
figur
lane
adcmvgag
figur
lane
expect
gag
protein
express
detect
lysat
cell
infect
unmodifi
viru
figur
lane
order
determin
hexonmodifi
vector
present
mper
epitop
within
hexon
region
purifi
unmodifi
gag
subject
western
blot
analysi
antibodi
mper
protein
detect
kda
protein
band
associ
gag
particl
figur
lane
respect
size
kda
band
correspond
expect
size
hexon
protein
mper
peptid
genet
incorpor
region
mper
protein
detect
wild
type
particl
figur
lane
forego
studi
valid
abil
deriv
stabl
vector
incorpor
mper
within
hexon
establish
technic
feasibl
allow
us
place
larg
epitop
within
hexon
next
sought
explor
function
util
modifi
vector
end
perform
elisa
assay
verifi
hiv
mper
motif
access
virion
surfac
figur
assay
vari
amount
purifi
virus
immobil
well
elisa
plate
incub
antibodi
result
show
signific
bind
antibodi
gag
wherea
bind
seen
respons
adcmvgag
control
result
indic
reactiv
mper
epitop
properli
expos
virion
surfac
incorpor
within
order
determin
capabl
antibodi
bind
capsidincorpor
antigen
dosedepend
manner
doserespons
elisa
assay
perform
antibodi
singl
concentr
follow
virus
adcmvgag
gag
appli
elisa
plate
follow
addit
serial
dilut
antibodi
predict
antibodi
bound
gag
dose
depend
manner
figur
data
suggest
mper
epitop
present
within
hexon
nativ
conform
recogn
monoclon
hiv
neutral
antibodi
previou
studi
shown
capsid
modif
well
transgen
incorpor
compromis
viral
growth
characterist
order
ensur
normal
viral
growth
inhibit
epitop
andor
transgen
incorpor
viral
particlegenom
perform
growth
kinet
assay
vector
use
studi
obtain
quantit
understand
effect
respect
vector
titer
cell
full
cpe
achiev
order
determin
growth
kinet
data
illustr
unmodifi
highest
titer
ifuml
produc
full
cpe
hour
postinfect
adcmvgag
also
produc
full
cpe
postinfect
howev
adcmvgag
titer
sever
order
magnitud
lower
gag
show
compar
titer
adcmvgag
control
vector
express
fulllength
envelop
protein
adcmvenv
reach
full
cpe
hour
postinfect
yield
slowest
growth
kinet
rel
titer
reach
full
cpe
hour
postinfect
figur
growth
kinet
pattern
similar
capsid
transgen
modifi
vector
develop
laboratori
previou
work
shown
capsid
modif
may
result
product
thermoli
vector
therefor
perform
thermost
assay
respect
vector
particular
assay
import
due
complex
natur
incorpor
antigen
ie
mper
andor
gag
hexonmodifi
vector
well
control
vector
subject
heat
variou
time
point
minut
vector
use
infect
cell
viral
infecti
titer
redetermin
heat
use
assay
accord
thermost
assay
least
infecti
vector
show
dramat
infect
reduct
rel
follow
incub
minut
figur
thermost
result
similar
observ
transgeneencod
capsidmodifi
vector
laboratori
verifi
immun
potenti
vector
hiv
next
sought
determin
capabl
elicit
antihiv
immun
respons
mice
equal
number
vector
use
immun
balbc
mice
via
intramuscular
rout
sera
collect
mice
elisa
assay
variou
day
prime
boost
purifi
mper
antigen
peptid
bound
elisa
plate
plate
incub
immun
mice
sera
bind
detect
hrpconjug
secondari
antibodi
amount
antimp
antibodi
sera
calcul
base
standard
antibodi
curv
dilut
data
demonstr
bind
sera
mice
immun
adcmvenv
adcmvgag
mper
plate
time
point
contrari
immun
ad
contain
capsidincorpor
mper
antigen
elicit
antimp
specif
respons
allow
format
mperspecif
antibodi
serum
figur
immun
respons
observ
earliest
time
point
observ
day
postprim
dpp
peak
immun
respons
observ
capsid
incorpor
mper
vector
dpp
also
correspond
day
postboost
dpb
dpp
determin
concentr
antibodi
slight
declin
mper
antibodi
sera
dpp
observ
mice
vaccin
capsidmodifi
vector
correspond
dpb
dpb
mper
antibodi
level
sera
determin
summari
gag
elicit
respons
vaccin
mice
mperspecif
respons
increas
boost
import
note
envelop
express
adcmvenv
hiv
variant
epitop
insert
hexon
peptid
ident
sequenc
env
mper
region
transgen
express
vector
env
ie
process
point
mutat
within
transgen
express
env
next
perform
experi
determin
quantit
aspect
isotypespecif
humor
immun
respons
gener
respons
antihiv
immun
vector
sera
collect
mice
elisa
assay
dpp
dpb
describ
previous
purifi
mper
antigen
peptid
bound
plate
plate
incub
immun
mous
sera
bind
detect
hrp
conjug
secondari
antibodi
gag
vector
produc
isotypespecif
antimp
humor
respons
vaccin
mice
wherea
isotypespecif
respons
seen
mice
vaccin
adcmvgag
adcmvenv
presenc
isotyp
correspond
activ
respect
figur
cell
activ
import
host
protect
foreign
antigen
incorpor
epitop
hexon
protein
may
interfer
viral
infect
andor
reduc
recognit
neutral
antibodi
nab
therefor
compar
infect
gag
origin
adcmvgag
viru
presenc
absenc
nab
found
human
ascit
describ
previous
absenc
ascit
frequenc
cell
express
gag
infect
adcmvgag
gag
respect
indic
incorpor
epitop
hexon
protein
vector
reduc
viru
infect
figur
compar
unmodifi
vector
presenc
epitop
alter
neutral
nab
present
human
ascit
figur
therefor
epitop
facilit
escap
preexist
antiadenovir
humor
immun
respons
probabl
due
polyclon
natur
ascit
nab
previou
experi
reli
immun
recognit
capsid
protein
address
capac
modifi
vector
transduc
cell
direct
express
deliv
antigenencod
transgen
vivo
test
capac
hexonmodifi
vector
deliv
induc
express
hiv
gag
transgen
measur
expans
gagspecif
tcell
variou
consecut
time
point
follow
vaccin
prime
boost
later
measur
persist
memori
cell
equal
amount
viral
particl
use
immun
mice
blood
collect
mice
dpp
dpb
tcell
subject
gag
tetram
stain
result
figur
illustr
mous
immun
gag
adcmvgag
observ
compar
gag
respons
immun
group
accept
result
data
show
loss
gag
respons
due
incorpor
mper
epitop
within
hexon
capsid
mous
immun
vector
result
background
level
tcell
activ
addit
gag
vector
allow
boost
gag
transgen
express
compar
adcmvgag
vector
figur
result
statist
signific
p
intracellular
stain
tetram
posit
cell
observ
group
data
shown
confirm
function
integr
expand
hiv
gagspecif
cell
develop
novel
ad
vector
potenti
optim
ad
vaccin
approach
strategi
involv
insert
antigen
epitop
region
ad
capsid
protein
hexon
stimul
epitopespecif
antibodi
respons
follow
vaccin
method
offer
abil
compar
rang
ident
epitop
incorpor
within
hvr
antigen
optim
current
studi
first
kind
genet
incorpor
hiv
antigen
within
hexon
alon
combin
genom
incorpor
transgen
hiv
antigen
express
studi
success
incorpor
hiv
mper
region
evidenc
pcr
western
blot
analysi
purifi
wholeviru
elisa
figur
believ
character
bind
antibodi
necessari
perform
addit
elisa
experi
use
purifi
protein
sera
vaccin
mice
abl
observ
slight
bind
whole
protein
sera
mice
vaccin
ad
vector
present
mper
within
hexon
capsid
data
shown
specul
bind
would
increas
abl
obtain
ident
purifi
protein
present
capsidincorpor
mper
sequenc
possibl
due
diverg
hiv
protein
structur
reagent
avail
also
perform
elisa
assay
hiv
pseudo
particl
sera
vaccin
mice
data
shown
result
similar
seen
purifi
protein
specul
difficult
detect
bind
hiv
particl
due
need
optim
assay
andor
limit
amount
molecul
avail
singl
hiv
virion
env
molecul
per
virion
like
mper
epitop
insert
ad
hexon
present
conform
would
present
within
context
hiv
virion
therefor
advantag
disadvantag
antigen
capsidincorpor
approach
advantag
approach
includ
fact
obvious
much
easier
insert
small
peptid
hiv
hexon
compar
insert
correctli
fold
version
full
hiv
protein
hexon
would
like
imposs
howev
despit
fact
mper
present
might
differ
respect
ad
capsid
incorpor
compar
mper
express
hiv
virion
abl
detect
presenc
epitop
mean
human
hiv
monoclon
antibodi
recogn
amino
acid
within
mper
figur
wherea
abl
detect
presenc
mper
use
human
hiv
monoclon
antibodi
bind
amino
acid
linear
epitop
immedi
ctermin
epitop
contain
mper
data
shown
observ
suggest
mper
conform
similar
ident
present
hiv
virion
one
advantag
antigen
capsidincorpor
approach
nonglycosyl
mper
may
immunogen
absenc
glycanshield
hexonpeptid
present
approach
abl
address
addit
interest
question
eg
glycosyl
site
within
around
mper
region
affect
immunogen
plan
rigor
examin
abil
peptid
present
approach
produc
neutral
antibodi
perhap
guinea
pig
rabbit
system
mper
incorpor
combin
transgen
express
observ
growth
kinet
figur
thermost
figur
chang
similar
capsidmodifi
vector
gener
studi
although
appear
substanti
growth
kinet
thermost
differ
gag
figur
appear
signific
differ
cellular
gag
immun
respons
gener
vaccin
gag
figur
importantli
vaccin
hexonmodifi
vector
studi
result
humor
antihiv
respons
noteworthi
fulli
explor
antigen
capsidincorpor
strategi
antimp
humor
respons
could
boost
homolog
ad
vector
administr
dpp
mper
respons
mice
vaccin
hexonmodifi
vector
approxim
time
higher
use
adcmvgag
adcmvenv
vector
critic
find
studi
appear
vaccin
adcmvenv
yield
antibodi
respons
find
could
explain
variou
way
sinc
hiv
env
protein
precursor
protein
catalyz
proteas
give
final
product
possibl
product
mask
antibodi
recognit
find
might
indic
antigen
capsidincorpor
strategi
superior
antigen
transgen
express
regard
gener
vivo
immun
respons
mper
andor
antigen
order
confirm
valid
result
obtain
vaccin
group
separ
set
elisa
experi
perform
wherebi
sera
vaccin
mice
bound
unmodifi
ad
vector
sera
vaccin
group
bound
unmodifi
wild
type
equal
well
indic
equal
vaccin
adcmvgag
adcmvenv
gag
data
shown
addit
antimp
isotypespecif
respons
observ
mice
vaccin
mper
capsidmodifi
vector
figur
similar
result
seen
data
shown
howev
mper
igaspecif
respons
observ
data
shown
expect
find
much
mper
igaspecif
immun
respons
vaccin
vector
due
rout
vector
administr
howev
plan
investig
igaspecif
respons
context
target
hexonmodifi
vector
combin
altern
rout
administr
humor
immun
standpoint
subclass
reduc
saliva
upon
hiv
infect
total
secretori
iga
level
reduc
later
diseas
stage
salivari
iga
neutral
block
epitheli
transmigr
instanc
salivari
iga
function
hiv
figur
compar
infect
gag
adcmvgag
vector
presenc
absenc
nab
found
human
ascit
vector
equal
neutral
presenc
human
ascit
fluid
expect
gag
would
neutral
lesser
degre
adcmvgag
presenc
human
ascit
howev
sinc
case
specul
polyclon
antibodi
found
human
ascit
fluid
mask
addit
singl
epitop
incorpor
within
hexon
region
also
specul
might
observ
differ
result
assay
use
monoclon
antibodi
target
hexon
region
insert
incorpor
monoclon
antibodi
use
presenc
ascit
fluid
gag
might
escap
neutral
larg
compar
adcmvgag
howev
possibl
explor
time
diminish
clinic
benefit
vector
importantli
gag
vector
allow
boost
gag
transgen
product
compar
wild
type
gag
express
vector
figur
result
statist
signific
p
import
find
two
reason
indic
potenti
second
administr
vector
without
diminish
product
transgen
demonstr
incorpor
hiv
epitop
within
detriment
effect
vivo
transgen
product
figur
specul
mpermodifi
vector
allow
boost
compar
adcmvgag
possibl
gag
ad
elicit
less
immun
respons
possibl
mper
epitop
reduc
immunogen
vector
also
possibl
antimp
antibodi
fraction
neutral
regard
hexonmodifi
boost
similar
result
seen
experi
perform
abe
colleagu
studi
support
concept
modifi
hexon
thwart
neutral
antibodi
promot
cellular
immun
respons
rang
studi
investig
viral
antigen
capidincorpor
strategi
viabl
mean
improv
vaccin
mani
diseas
infect
context
due
controversi
hiv
step
trial
continu
hiv
epidem
group
employ
antigen
capsidincorpor
strategi
make
stride
hivaid
attempt
make
safe
effect
hiv
vaccin
main
vector
system
util
deriv
hiv
vaccin
includ
human
rhinoviru
hrv
adbas
vector
system
respect
hrv
system
research
construct
hrv
hiv
chimera
effort
stimul
immun
furthermor
along
line
effort
develop
hiv
vaccin
research
within
group
gener
combinatori
librari
hrv
capidincorpor
epitop
result
indic
success
elicit
antibodi
whose
activ
mimic
effect
commerci
clinic
ad
develop
hiv
vaccin
progress
preferenti
vector
system
hrv
plastic
ad
gener
exce
current
rhinoviru
system
exampl
rel
small
rna
viru
rhinoviru
platform
display
array
limit
copi
singl
epitop
comparison
ad
hexonincorpor
display
platform
could
present
array
epitop
copi
pix
incorpor
display
platform
could
potenti
present
array
epitop
copi
anoth
signific
differ
two
platform
number
local
success
util
heterolog
epitop
insert
regard
knowledg
human
rhinoviru
platform
util
singleepitop
insert
site
major
immunogen
portion
viral
loop
contrast
ad
vector
platform
could
potenti
allow
incorpor
mper
epitop
four
structur
distinct
local
includ
hexon
protein
ix
penton
base
andor
fiber
lastli
contrast
rhinoviru
lack
capac
ad
platform
suffici
code
capac
allow
transgen
express
combin
present
differ
antigen
viral
capsid
surfac
despit
note
limit
rhinoviru
platform
one
attract
featur
previous
mention
develop
mutagen
librari
human
rhinoviru
chimera
display
random
residu
repres
mper
epitop
regard
worth
mention
lab
previous
develop
similar
approach
screen
identifi
heterolog
amino
acid
sequenc
insert
incorpor
adenoviru
fiber
knob
region
use
modifi
phage
display
approach
overal
extens
ongo
vector
develop
group
other
ad
platform
offer
dynam
level
plastic
translat
advantag
multipl
vaccin
develop
taken
togeth
current
studi
demonstr
util
hiv
mper
epitop
incorpor
combin
hiv
gag
transgen
incorpor
within
ad
genom
previou
work
describ
precis
optim
antigen
size
configur
capsid
incorpor
base
abil
manipul
capsid
protein
well
intern
gene
loci
abl
establish
novel
vector
allow
product
multival
vector
may
act
vaccin
cocktail
vector
capsidincorpor
antigen
potenti
vaccin
patient
hiv
produc
robust
antihiv
humor
cell
respons
data
illustr
divers
immunolog
responseprofil
vaccin
capsidmodifi
vector
compar
vector
contain
wild
type
hexon
fact
provid
rational
heterolog
prime
boost
strategi
hexonmodifi
vector
follow
wild
type
hexon
vector
could
potenti
achiev
even
greater
antihiv
immun
respons
addit
vector
may
great
potenti
circumv
drawback
seen
gener
popul
relat
pei
futur
plan
includ
transit
vector
gutless
system
order
determin
durat
qualiti
hiv
antibodi
product
combin
gutless
system
plan
decreas
pei
use
chemic
conjug
polyethylen
glycol
andor
ad
vector
chimera
